Cargando…

Is high-density lipoprotein a modifiable treatment target or just a biomarker for cardiovascular disease?

Epidemiological data strongly support the inverse association between high-density lipoprotein cholesterol concentration and cardiovascular risk. Over the last three decades, pharmaceutical strategies have been partially successful in raising high-density lipoprotein cholesterol concentration, but c...

Descripción completa

Detalles Bibliográficos
Autor principal:	Whyte, Martin B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691666/ https://www.ncbi.nlm.nih.gov/pubmed/31448115 http://dx.doi.org/10.1177/2048004019869736

Ejemplares similares

Neutrophils as a Novel Target of Modified Low-Density Lipoproteins and an Accelerator of Cardiovascular Diseases
por: Obama, Takashi, et al.
Publicado: (2020)

Aggregation Susceptibility of Low-Density Lipoproteins—A Novel Modifiable Biomarker of Cardiovascular Risk
por: Öörni, Katariina, et al.
Publicado: (2021)

High-Density Lipoproteins in Non-Cardiovascular Diseases
por: Zanotti, Ilaria
Publicado: (2022)

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk
por: Hafiane, Anouar, et al.
Publicado: (2015)

PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers
por: González, Fátima E. Murillo, et al.
Publicado: (2019)

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
por: Kapur, Navin K, et al.
Publicado: (2008)

High density lipoproteins-based therapies for cardiovascular disease
por: Gao, Xuan, et al.
Publicado: (2010)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants
por: Kim, Hye Jun, et al.
Publicado: (2023)

Presepsis biomarker: high-density lipoprotein
por: Al-Zaidawi, S
Publicado: (2014)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future
por: Julve, Josep, et al.
Publicado: (2021)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future
por: Julve, Josep, et al.
Publicado: (2021)

Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease
por: Estrada-Luna, Diego, et al.
Publicado: (2018)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II
por: Julve, Josep, et al.
Publicado: (2022)

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
por: Kornmueller, Karin, et al.
Publicado: (2019)

The Impact of Lipoprotein Apheresis on Oxidative Stress Biomarkers and High-Density Lipoprotein Subfractions
por: Mickiewicz, Agnieszka, et al.
Publicado: (2020)

Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease
por: Su, J, et al.
Publicado: (2005)

Modified lipoproteins in periodontitis: a link to cardiovascular disease?
por: Ljunggren, Stefan, et al.
Publicado: (2019)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
por: Besler, Christian, et al.
Publicado: (2012)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins
por: Hong, Brian V., et al.
Publicado: (2023)

Dual-modified natural high density lipoprotein particles for systemic glioma-targeting drug delivery
por: Cui, Lin, et al.
Publicado: (2018)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

High-Density Lipoproteins in Kidney Disease
por: Kon, Valentina, et al.
Publicado: (2021)

High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training
por: Ahn, Nayoung, et al.
Publicado: (2016)

Modified Low Density Lipoprotein and Lipoprotein-Containing Circulating Immune Complexes as Diagnostic and Prognostic Biomarkers of Atherosclerosis and Type 1 Diabetes Macrovascular Disease
por: Orekhov, Alexander N., et al.
Publicado: (2014)

High-Density Lipoprotein-Targeted Therapies for Heart Failure
por: Mishra, Mudit, et al.
Publicado: (2020)

Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
por: Coimbra, Susana, et al.
Publicado: (2021)

Oxidized and electronegative low-density lipoprotein as potential biomarkers of cardiovascular risk in obese adolescents
por: de Freitas, Maria Camila Pruper, et al.
Publicado: (2018)

High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need
por: Cimmino, Giovanni, et al.
Publicado: (2014)

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
por: McTaggart, Fergus, et al.
Publicado: (2008)

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Li, Yi-Heng, et al.
Publicado: (2020)

High-density Lipoproteins (HDLs): Biomarkers or bio-actors of abdominal aortic aneurysmal disease?
por: Meilhac, Olivier
Publicado: (2019)

Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study
por: Hajian-Tilaki, Karimollah, et al.
Publicado: (2020)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases
por: Ivanova, Ekaterina A., et al.
Publicado: (2017)

Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease
por: Sato, Masaki, et al.
Publicado: (2023)

Association of High‐Density Lipoprotein Particles and High‐Density Lipoprotein Apolipoprotein C‐III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi‐Ethnic Study of Atherosclerosis
por: Lamprea‐Montealegre, Julio A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fdvu2vi62lev2b197ejpjcttkf